Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

InternetNews May 5, 2009 Kenneth Corbin	Apple, Google Facing Antitrust Scrutiny: Report FTC said to be examining whether sharing board members is anti-competitive.
The Motley Fool October 12, 2009 Anders Bylund	Google Battles the Antitrust Demons Google has waved a fond farewell to board member Arthur Levinson, breaking almost all of ties that bind it to crosstown rival Apple.
The Motley Fool July 9, 2009 Anders Bylund	Eric Schmidt Should Resign! Google CEO Eric Schmidt has held a seat on Apple's board of directors since 2006. It's probably high time for him to get out of that boardroom.
The Motley Fool August 3, 2009 Anders Bylund	Apple Says, "That's It, Schmidt!" Eric Schmidt has stepped down from his duties at the company. "Eric's effectiveness as an Apple Board member will be significantly diminished," said Apple CEO Steve Jobs, "since he will have to recuse himself from even larger portions of our meetings."
InternetNews July 10, 2009 Kenneth Corbin	Google's Schmidt Rethinks Apple Board Seat First in mobile devices, and soon, on the OS: Apple and Google seem to be becoming direct competitors.
The Motley Fool April 6, 2010 Anders Bylund	This Billionaire Picks Google Over Amazon And so the web is less of a tangled mess.
BusinessWeek January 12, 2004	Arthur Levinson The scientist-turned-CEO plans to move Genentech into the pharmaceutical big leagues.
BusinessWeek October 6, 2003 Arlene Weintraub	Genentech's Medicine Man CEO Arthur Levinson got the biotech pioneer off life support. Will it finally deliver on its promises?
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
InternetNews January 22, 2010	Google Talks China Plans, iPhone Loss Rumors Schmidt and others respond to talk that Microsoft's Bing might replace Google on the iPhone, and what the search leader thinks about its future in China.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool April 10, 2006 Rich Smith	Foolish Forecast: Genentech Under the Microscope Despite Genentech's gross margins declining somewhat over the past 18 months, the company has consistently expanded its operating and net margins. Investors, take note.
The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.
InternetNews August 30, 2006 Michael Hickins	Will Schmidt Help Apple Set iTunes Free? Long-time chum Eric Schmidt could tell Steve Jobs a thing or two about dealing directly with consumers on the Internet.
InternetNews October 15, 2009	Google Tops Estimate as Signs Point to Rebound Google turns in a healthy third quarter and says the worst is behind us.
InternetNews July 16, 2009	Google Stands Strong in Second-Quarter Results Google tops estimates, posts a modest uptick in revenue and sees solid earnings in a tough ad economy.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
InternetNews August 3, 2009 Michelle Megna	Google CEO Resigns From Apple Board As the two heavyweights' businesses converge and regulators raise troubling questions, Schmidt bows out.
IndustryWeek November 17, 2010	Board Member Today; CEO Tomorrow The number of Fortune 1000 directors who became the CEOs of the companies on whose boards they served more than doubled in the past year.
BusinessWeek June 27, 2005 Joseph Webe	How The Best Boards Stay Clued In Director John A. Krol says a culture of openness has helped turn Tyco around.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
U.S. Banker April 2010 Michael Sisk	Boardroom Burdens Bank directors must be more hands-on than ever, exercising tighter control over management and setting strategic direction. Here are five issues that need attention now.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
CIO November 14, 2012 Kim S. Nash	Boards Want to Learn About Emerging IT Issues Directors admit they aren't adequately engaged in topics such as social media and IT-enabled business innovation
The Motley Fool June 6, 2007 Anders Bylund	All Aboard: Google The only time we hear about a board of directors is when its members are up to no good. Investors, take a peek behind the curtain at the Googleplex. Who runs the show at Google, and how are they organized?
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool April 8, 2009 Alyce Lomax	Corporate Boards Need to Wake Up One of investors' biggest problems -- whether they know it or not -- has been a tendency toward ineffective, entrenched boards of directors that don't do their primary job, which is to look out for shareholder interests.
The Motley Fool June 1, 2007 Selena Maranjian	Ups and Downs for Women A new report on the progress of women in the workplace features some interesting results. Why does this topic matter to investors? Some studies suggest that having more women on a board of directors can lead to better governance.
The Motley Fool July 12, 2007 Brian Orelli	Supporting the Little Company Tercica gets a partnership with Genentech. As part of the deal, Genentech will purchase $4 million in Tercica stock for about $5.65 per share. Some investors think that Genentech is underpaying.
The Motley Fool March 17, 2009 Anders Bylund	When Android Met iPhone This supposed tech rivalry is actually true love at first sight.
InternetNews November 7, 2006 David Needle	Google Wants to Make Search History Portable Web 2.0 Summit captures latest Web buzz.
The Motley Fool August 30, 2006 Rick Aristotle Munarriz	Apple Googles for Greatness The Mac maker taps Google's CEO for its board. This is just one more way for Google to draw a thicker battle line against Microsoft.
Bank Director 4th Quarter 2009	For Your Review What financial institutions directors are thinking about-the results of 2009 research by Corporate Board Member and PricewaterhouseCoopers LLP... What's ahead for banking...
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
BusinessWeek July 1, 2010 Doherty & Waters	Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand
BusinessWeek November 25, 2009 Arlene Weintraub	Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance.
The Motley Fool February 25, 2009 Brian Orelli	Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
The Motley Fool July 12, 2007 Brian Lawler	Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried.
HBS Working Knowledge July 11, 2012 Jay Lorsch	Book Excerpt: 'The Future of Boards' In an excerpt from "The Future of Boards," the author discusses why directors are newly questioning their roles.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
InternetNews August 5, 2004 Susan Kuchinskas	Google Flunks Governance With an insider board and improper securities sales, who's minding the store?
InternetNews April 19, 2007 Michael Hickins	Google 'Ecstatic' Over Earnings Some of Google's moves may seem far afield, but according to CEO Eric Schmidt, it all comes back to supporting its core ad-selling business.